In age-related macular degeneration and a host of other macular diseases, a variety of reasons lead to the growth of neovascularization in the eye (choroid and retina), which is brittle and prone to bleeding, leakage, and edema, eventually leading to scarring and blindness. Anti-neovascularization drugs are to stop the growth of neovascularization, reduce leakage, reduce edema, and thus stabilize or improve vision. At present, anti-angiogenic drugs have a wide range of applications: 1, macular edema caused by various causes (including diabetic macular edema, macular edema caused by various diseases such as post-cataract surgery or post uveitis); 2, choroidal neovascularization membrane formation caused by various reasons (including age-related macular degeneration, highly myopic macular degeneration, mesophthalmos, etc.); 3, retinal neovascularization (e.g., diabetic retinopathy, Retinal neovascularization (such as diabetic retinopathy, venous obstruction, retinal vein periphlebitis, Coats’ disease, choroidal osteoma, choroidal hemangioma and other causes of retinal neovascularization or microangiopathy); 4, retinal vein obstruction; 5, neovascular glaucoma and other diseases.